Article Text

Download PDFPDF

Response to: ‘NCF1-339 polymorphism and systemic lupus erythematosus’ by Joob and Wiwanitkit
  1. Carl Petrus Linge,
  2. Anders Bengtsson
  1. Department of Clinical Sciences, Section of Rheumatology, Faculty of Medicine, Lund University, Lund, Sweden
  1. Correspondence to Dr Carl Petrus Linge, Department of Clinical Sciences, Section of Rheumatology, Faculty of Medicine, Lund University, Lund, Sweden; petrus.linge{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In the comment by Joob and Wiwanitkit,1 questions are raised regarding the role of the NCF1-339 rs201802880 polymorphism in systemic lupus erythematosus (SLE) in our recent publication.2 One concern relates to the possibility of a molecular weight change due to the polymorphism and if this could alter phenotypic expression. Studies of functional effects of the polymorphism in question have been demonstrated both in this report as well as in earlier work by our group.3 4 NCF1 (p47phox) plays an vital role in the assembly and stability of the extensively studied nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 complex5 and the nucleotide shift from C to T at NCF1-339 alters the amino acid from arginine to histidine at a PX domain of the NCF1 protein.6 This domain has been shown to be of crucial importance in the membrane binding and mutations in the NCF1-339 position reduces reactive oxygen species (ROS) response,4 7 providing a mechanistic explanation for the observed ROS-decreasing effect of the polymorphism. We have not considered comparing molecular weight of polymorphic NCF1 and non-polymorphic molecules. Placing a polymorphism in a functional context provided by current and previous findings is far more relevant in our opinion. We find it unlikely that a potential molecular weight difference would add any significant information relevant to the biological/pathological context presented.

A second concern was raised about the potential role of other polymorphisms and possible functional consequences. Joob and Wiwanitkit are particularly interested in the putative effects of polymorphisms in the paraoxonase-1 gene and PAL-1. Our aim with this study was to determine the functional effect of NCF1-339 polymorphisms on neutrophil extracellular traps, type I interferon activity and to find potential associations with clinical phenotypes in SLE. The striking association between NCF1-339 polymorphisms and the antiphospholipid syndrome does not exclude associations with other polymorphisms but this was beyond the scope of this investigation.

Ethics statements

Patient consent for publication



  • Handling editor Josef S Smolen

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles